Our technology platform lends itself to a wide range of applications
We are developing a portfolio of products highlighted by a first-in-class vaccine for Respiratory Syncytial Virus (RSV), serotype-independent vaccine candidates against Streptococcus pneumoniae and Coronaviruses prophylactic approaches.
To further advance our platform and offer tangible solutions to health conditions, we welcome collaboration opportunities and various partnering options.
Respiratory syncytial virus (RSV) is a prevalent, contagious respiratory pathogen, the leading cause of bronchitis and pneumonia, affecting more than 64 million people each year worldwide. In vulnerable patients (infants and elderly) it can cause significant morbidity and mortality. Currently there is no vaccine available in the market and the only prophylaxis is a monoclonal Ab (palivizumab) restricted to high-risk pediatric patients. With V-306 Virometix offers a differentiated approach to RSV vaccine development. Our vaccine candidate – already in clinical phase I – demonstrates strong, durable, specific and protective immune responses, with minimal risk of vaccine-associated enhanced respiratory disease (VAERD).
Universal Pneumococcal Vaccine
Streptococcus pneumoniae infections cause diseases with considerable morbidity and mortality. Polysaccharide or conjugated vaccines induce serotype-specific antibodies, limiting clinical effectiveness. Emergence of new bacterial serotypes necessitate a new vaccination approach. Virometix is developing an epitope-based, serotype-independent, pneumococcal vaccine based on novel immunodominant, highly conserved antigens. The vaccine candidates are being developed in collaboration with the Children’s Hospital in Athens.
Virometix is focusing on the development of vaccine candidates with broad protection against a diverse number of coronaviruses. Our epitope-focused SVLP-based vaccine aims to target specific regions of the Receptor Binding Domain (RBD) of the Spike protein. Proof-of-concept studies are currently ongoing using SARS-CoV-2, where five Synthetic Antigen Mimetics (SAM) were rapidly designed and synthesized for an optimal neutralization response.
Effective antigen delivery and a strong and durable response is the basis for successful cancer vaccines. The SVLP approach, with its modular and flexible design, the inherent adjuvant properties and other immune system activators, lends itself to the development of particle-based vaccines against cancer: SVLPs displaying cancer antigens are optimally presented to the immune system and trigger cytotoxic T-cell activation in vitro and in vivo. Virometix is currently evaluating a number of options to provide best-in-class therapeutic solutions in cancer.